Mitoxantrone + Etoposide
Mitoxantrone  10 mg/m2/d iv over 15 min d1-5
Etoposide (VP-16) 100 mg/m2/d iv over 30 min d1-5
If no CR but blast reduction > 50%, a second course is administered
If CR, consolidation chemotherapy with
Mitoxantrone 8 mg/m2/d iv d1-5
Etoposide (VP-16) 75 mg/m2/d iv d1-5
Cytarabine (Ara-C) 75 mg/m2 iv q12hrs d1-5

Cytarabine + Mitoxantrone
Cytarabine (Ara-C) 500 mg/m2 iv q12h x 12 doses d1-6
Mitoxantrone  5 mg/m2/d iv d1-5

ADE
Course 1
Cytarabine (Ara-C) 100 mg/m2 iv push q12h d1-10 (20 doses)
Daunorubicin 50 mg/m2 iv slow push d1, 3, 5 (3 doses)
Etoposide (VP-16) 100 mg/m2/d iv over 1 h d1-5 (5 doses)
Course 2
Cytarabine (Ara-C) 100 mg/m2 iv push q12h d1-8 (16 doses)
Daunorubicin 50 mg/m2 iv slow push d1, 3, 5 (3 doses)
Etoposide (VP-16) 100 mg/m2/d iv over 1 h d1-5 (5 doses)

FLAG-IDA
Fludarabine 30 mg/m2/d iv over 30 min d1-5
Cytarabine (Ara-C) 2 g/m2/d iv over 4 hrs, 4 hrs after fludarabine, d1-5
Idarubicin 10 mg/m2/d iv d1-3
Filgrastim 5 mcg/kg/d sc to begin day 6 until neutrophil recovery

Cladribine
Cladribine (2-CdA) 8.9 mg/m2/d civi d1-5

CLAG
Cladribine (2-CdA) 5 mg/m2/d iv over 2 hrs d1-5
Cytarabine (Ara-C) 2 g/m2/d iv over 4 hrs d1-5
Filgrastim  300 mcg sc d0-5

CLAG-M
Cladribine (2-CdA) 5 mg/m2/d iv over 2 hrs d1-5
Cytarabine (Ara-C) 2 g/m2/d iv over 4 hrs starting 2 hrs after cladribine d1-5
Mitoxantrone  10 mg/m2/d iv d1-3
Filgrastim  300 mcg sc d0-5
If PR, a second course of CLAG-M is given
Once CR achieved, proceed with following consolidation chemotherapy
Course 1
Cytarabine (Ara-C) 1.5 g/m2/d iv d1-3
Mitoxantrone 10 mg/m2/d iv d3-5
Course 2
Cytarabine (Ara-C) 2 g/m2 iv q12h x 6 doses d1, 3, 5

Gemtuzumab
Gemtuzumab 9 mg/m2 iv q2w x 2 doses